Patents Assigned to Chancellor Master and Scholars of the University of Oxford
-
Publication number: 20130237567Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.Type: ApplicationFiled: April 25, 2013Publication date: September 12, 2013Applicants: The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
-
Patent number: 8501999Abstract: The process provided herein is concerned with recovery of hydrocarbons from sulfones using an individual alkali and alkaline-earthy base and a mixture of thereof. As the starting materials are sulfones generated by ODS and commercially inexpensive alkali and alkaline-earth bases, the cost and ecological impact of solid waste disposal is minimized.Type: GrantFiled: November 4, 2010Date of Patent: August 6, 2013Assignees: Saudi Arabian Oil Company, The Chancellor, Masters and Scholars of the University of OxfordInventors: Farhan M. Al-Shahrani, Tiancun Xiao, Huahong Shi, Malcolm L. H. Green
-
Publication number: 20130195798Abstract: One can treat a viral infection by first administering at least one first antiviral compound for a first time period and then, after the end of the first time period, concurrently or subsequently administering the at least one first antiviral compound and at least one second antiviral compound for a second period. In some cases, after the end of the second period, the same at least one second antiviral compound that was administered during the second time period may be administered for a third time period without concurrent or subsequent administration of the at least one first antiviral compound.Type: ApplicationFiled: November 21, 2012Publication date: August 1, 2013Applicants: The Chancellors, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: United Therapeutics Corporation, The Chancellors, Masters and Scholars of the Univ
-
Publication number: 20130150405Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Togaviridae family using iminosugars, such as DNJ derivatives.Type: ApplicationFiled: February 7, 2013Publication date: June 13, 2013Applicants: The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of Oxford
-
Patent number: 8450345Abstract: Provided are methods of treating or preventing viral infections caused by or associated with a Dengue virus using iminosugars.Type: GrantFiled: February 22, 2010Date of Patent: May 28, 2013Assignees: The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
-
Patent number: 8426445Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives.Type: GrantFiled: June 11, 2010Date of Patent: April 23, 2013Assignees: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of OxfordInventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
-
Patent number: 8367705Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Bunyaviridae or Togaviridae family using iminosugars, such as DNJ derivatives.Type: GrantFiled: June 11, 2010Date of Patent: February 5, 2013Assignees: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of OxfordInventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
-
Patent number: 8188313Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.Type: GrantFiled: September 13, 2011Date of Patent: May 29, 2012Assignees: The University of Birmingham, Chancellor Masters and Scholars of the University of Oxford, Ludwig Institute for Cancer ResearchInventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
-
Patent number: 8039670Abstract: There are disclosed compound of formula I, in which R1 represents a hydrophobic moiety adapted to occupy the C? channel of human CDId, R2 represents a hydrophobic moiety adapted to occupy the A? channel of human CDId, such that R1 fills at least at least 30% of the occupied volume of the C? channel compared to the volume occupied by the terminal nC14H29 of the sphingosine chain of ?-galactosylceramide when bound to human CDId and R2 fills at least 30% of the occupied volume of the A? channel compared to the volume occupied by the terminal nC25H51 of the acyl chain of ?-galactosylceramide when bound to human CDId R3 represents hydrogen or OH, Ra and Rb each represent hydrogen and in addition, when R3 represents hydrogen, Ra and Rb together may form a single bond, X represents or —CHA(CHOH)nY or —P(=0)(0?)0CH2(CH0H)mY, in which Y represents CHB1B2, n represents an integer from 1 to 4, m represents 0 or 1, A årepresents hydrogen, one of B1 and B2 represents H, OH or phenyl, and the other represents hydrogen or oType: GrantFiled: October 25, 2006Date of Patent: October 18, 2011Assignees: Ludwig Institute for Cancer Research, Chancellor Master and Scholars of the University of Oxford, The University of BirminghamInventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
-
Patent number: 7816560Abstract: Long chain N-alkyl amino and imino compounds, oxa-substituted derivatives thereof, and pharmaceutical compositions including such compounds are described. The long chain N-alkyl group is a C8-C16 alkyl group. The long chain N-alkyl compounds and oxa-substituted derivatives thereof can be used in the treatment of viral infections, in particular hepatitis B virus or hepatitis C virus, in a cell or an individual. For example, the long chain N-alkyl compounds or oxa-substituted derivatives thereof can be derived from piperidines, pyrrolidines, phenylamines, pyridines, pyrroles, or amino acids.Type: GrantFiled: August 10, 2000Date of Patent: October 19, 2010Assignees: Thomas Jefferson University, The Chancellor, Masters and Scholars of the University of Oxford, United Therapeutics CorporationInventors: Nicole Zitzmann, Terry D. Butters, Frances M. Platt, Gary S. Jacob, Donald H. Picker, Sandra Carrouee, George W. J. Fleet, Raymond A. Dwek, David Durantel, Anand Mehta, Timothy M. Block
-
Publication number: 20090041776Abstract: The invention as described herein provides compositions and methods for cancer immunotherapy and cancer detection. In particular, the invention discloses plant-derived human monoclonal antibodies that bind human carcinoma antigens in cancer cell lines.Type: ApplicationFiled: April 23, 2008Publication date: February 12, 2009Applicants: Biotechnology Foundation, Inc., The Chancellor, Masters and Scholars of the University of Oxford, University of OxfordInventors: Hilary Koprowski, Kisung Ko, Pauline Rudd, Yoram Tekoah, Raymond Dwek
-
Publication number: 20080226664Abstract: The invention provides methods, compositions and kits for inducing and/or enhancing an immune response in a subject. The invention in some aspects includes polypeptide and nucleic acid molecules that induce and/or enhance an immune response. In some aspects of the invention, the polypeptide and/or nucleic acid molecules of the invention are useful to induce and/or enhance an immune response in a subject who has or is suspected of having cancer.Type: ApplicationFiled: September 9, 2004Publication date: September 18, 2008Applicants: Ludwig Institute for Cancer Research, Chancellors Masters and Scholars of the University of OxfordInventors: Lloyd J. Old, Sacha Gnjatic, Djordje Atanackovic, Vincenzo Cerundolo, Khoon-Lin Ling
-
Patent number: 7364739Abstract: The present invention relates to a lipopolysaccharide moiety comprising a conserved triheptosyl inner-core moiety of lipopolysaccharide substantially free of variable outer core oligosaccharide chain extension, and to vaccines obtaines therefrom which are cross-reactive for Haemophilus influenzae strains. The invention also relates to defined mutations in the biosynthetic machinery for lipopolysaccharide (LPS;) expression in Haemophilus influenzae useful to obtain the abovementioned moiety. The invention also relates to using conjugates of the LPS from the mutant strains so obtained to elicit a heterologous immune response against a wide range of disease-causing H. influenzae strains. More specifically, the invention relates to vaccines for prevention of bacterial infections comprising core lipopolysaccharide of Haemophilus influenzae.Type: GrantFiled: August 27, 2001Date of Patent: April 29, 2008Assignees: National Research Council of Canada, The Chancellor, Masters, and Scholars of the University of OxfordInventors: James C. Richards, Andrew Cox, Richard Moxon, Derek Hood, Elke K. H. Schweda, Martin Månsson
-
Publication number: 20070224648Abstract: Methods and compositions for the modulation of insulin secretion.Type: ApplicationFiled: September 19, 2006Publication date: September 27, 2007Applicant: The Chancellor, Masters and Scholars of the University of OxfordInventors: Roger Cox, Frances Ashcroft, Helen Freeman, Kenju Shimomura
-
Patent number: 7256005Abstract: Disclosed are methods for screening that may be used to identify an inhibitor of HCV p7 protein. The methods may include incorporating an HCV p7 protein into a membrane to create an HCV p7-containing membrane that has an increased permeability relative to a membrane that does not contain HCV p7 protein. The HCV p7 protein may be contacted with a test compound, and the permeability of this HCV p7-containing membrane then may be compared to an HCV p7-containing membrane in which the HCV p7 protein has not been contacted with the test compound. The inhibitor of HCV p7 protein may be identified by observing a decrease in the permeability of the HCV p7-containing membrane in which the HCV p7 protein has been contacted with the test compound.Type: GrantFiled: September 23, 2003Date of Patent: August 14, 2007Assignee: The Chancellor, Masters and Scholars of the University of OxfordInventors: Nicole Zitzmann, Raymond Allen Dwek Frs
-
Publication number: 20050138692Abstract: The invention as described herein provides compositions and methods for cancer immunotherapy and cancer detection. In particular, the invention discloses plant-derived human monoclonal antibodies that bind human carcinoma antigens in cancer cell lines.Type: ApplicationFiled: June 2, 2004Publication date: June 23, 2005Applicants: Biotechnology Foundation, Inc., The Chancellor, Masters and Scholars of the University of Oxford, University of OxfordInventors: Hilary Koprowski, Kisung Ko, Pauline Rudd, Yoram Tekoah, Raymond Dwek
-
Patent number: 6689742Abstract: The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.Type: GrantFiled: February 25, 2000Date of Patent: February 10, 2004Assignee: Chancellors, Masters and Scholars of the University of OxfordInventors: Vincenzo Cerundolo, Rodney Dunbar, Ji-li Chen
-
Patent number: 6682731Abstract: Complexes of SEQ ID NO: 12 and HLA-A2 can be used to generate CTLs. They can be supplemented with IL-6 and IL-12.Type: GrantFiled: March 23, 2000Date of Patent: January 27, 2004Assignees: Ludwig Institute for Cancer Research, The Chancellor Masters & Scholars of the University of Oxford, University of LeidenInventors: Alan Townsend, Judy Bastin, Thierry Boon-Falleur, Pierre Van Der Bruggen, Pierre Coulie, Thomas Gajewski, Cornelis J. M. Melief, Marjan J. W. Visseren, Martin W. Kast
-
Patent number: 6660749Abstract: Methods for treating lipid storage diseases using compounds that inhibit glucosyltransferase enzymes are disclosed herein. The invention relates to the treatment of lipid storage disease with compounds that inhibit glucosyltransferase activity in the affected cells. It relates particularly to the use of 1,5-dideoxy-1,5-imino-D-glucitol and derivatives thereof.Type: GrantFiled: September 17, 2002Date of Patent: December 9, 2003Assignee: Chancellor, Masters and Scholars of the University of OxfordInventors: Terry D. Butters, Frances M. Platt, Raymond A. Dwek
-
Patent number: 6465487Abstract: Methods for inhibiting morphogenesis of host cell membrane-budding viruses and infections caused thereby using compounds that inhibit host cell glucosidase or glucosyltransferase enzymes. Methods for treating lipid storage diseases using compounds that inhibit glucosyl transferance enzymes.Type: GrantFiled: December 10, 1998Date of Patent: October 15, 2002Assignees: Synergy Pharmaceuticals, Inc., Thomas Jefferson University, The Chancellor, Masters and Scholars of the University of OxfordInventors: Timothy M. Block, Raymond A. Dwek, Baruch S. Blumberg, Anand Mehta, Frances Platt, Terry D. Butters, Nicole Zitzmann